Carl Zeiss Meditec


Microsurgery leads the pack in Q4

07/12/18 -"although sales in the Ophthalmic Devices segment missed expectations in Q4, the fourth consecutive quarter of double-digit growth in the Microsurgery division ensured that FY17/18 revenue targets ..."

Pages
51
Language
English
Published on
07/12/18
You may also be interested by these reports :
20/02/19
Fresenius’s Q4 figures were pretty much in-line with our expectations adjusted for our too low assumption on FMC, as Helios came in stronger than ...

20/02/19
Impacted by higher production costs, increased investments into R&D and slower organic growth in the retail business, the adjusted EBIT came in at ...

20/02/19
FMC reported a more profitable Q4 without any restrucuring costs, which we had expected to clean up the company. The consensus was broadly met. ...

15/02/19
We assume 2018 is likely to end with mixed figures (covered by the divestment proceeds) and, according to the CEO, Mr Sturm, 2019 will also not fair ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO